{"id":"NCT01189487","sponsor":"Pfizer","briefTitle":"The Study of Unasyn-S 12g/Day for Community Acquired Pneumonia (CAP)","officialTitle":"A Multicenter, Unblinded, Non-Comparative Study Of Unasyn-S 12 G/Day Evaluating The Safety And Efficacy In Japanese Adult Subjects With Community Acquired Pneumonia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-10","primaryCompletion":"2011-04","completion":"2011-04","firstPosted":"2010-08-26","resultsPosted":"2012-05-18","lastUpdate":"2012-07-13"},"enrollment":47,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Pneumonia, Bacterial"],"interventions":[{"type":"DRUG","name":"ampicillin sodium/sulbactam sodium","otherNames":["Unasyn-S"]}],"arms":[{"label":"ampicillin sodium/sulbactam sodium","type":"EXPERIMENTAL"}],"summary":"Unasyn-S 12g/day (3 g four times a day) is the commonly used dosage depending on the severity for US, EU, China, Taiwan and Korea for over 20 years, however, Unasyn-S 12g/day has not yet been approved in Japan. The purpose of this trial is to evaluate the clinical efficacy and safety in Japanese adult subjects with community acquired pneumonia receiving ampicillin sodium/sulbactam sodium, 12g/day (3 g four times a day ) IV.","primaryOutcome":{"measure":"Response Rate (Clinical Response, Data Review Committee Assessment)","timeFrame":"End of treatment, Test of cure (7 days after End of treatment), Long term follow up (7 days after Test of cure)","effectByArm":[{"arm":"Ampicillin Sodium/Sulbactam Sodium","deltaMin":97.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":22,"countries":["Japan"]},"refs":{"pmids":["25533886","24102758"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A9231001&StudyName=The%20Study%20of%20Unasyn-S%2012g/day%20for%20Community%20Acquired%20Pneumonia%20%28CAP%29"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":47},"commonTop":["Alanine aminotransferase increased","Aspartate aminotransferase increased","Constipation","Blood alkaline phosphatase increased","Diarrhoea"]}}